Mhc binding peptide oligomers and methods of use
CA 2262001 C · Owner: President And Fellows Of Harvard College · Inventors: Rotzschke, Olaf; Falk, Kirsten; Strominger, Jack L.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed are oligomers comprising at least two MHC binding peptides joined by a flexible molecular linker. The MHC binding peptides can be MHC class I binding peptides or MHC class II binding peptides. Also disclosed is an oriented cloning method for producing such oligomers. The disclosed oligomers can be used, for example, in connection with methods for specifically activating or inhibiting the activation of CD4+ or CD8+ T cells. Such methods provide therapeutic approaches for the treatment of tumors autoimmune , disorders, allograft rejection and allergic reactions.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 5, 1997 and granted May 20, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 5, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 5, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.